China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Independent Director Annual Performance Report for 2025
As an independent director of China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (hereinafter referred to as "China Resources Sanjiu" or "the Company"), I have strictly adhered to the provisions of the Company Law, the Management Measures for Independent Directors of Listed Companies, the Articles of Association, and the Working System for Independent Directors of the Company. I have faithfully, diligently, and responsibly fulfilled my duties as an independent director, proactively understanding the Company's production and operational status, attending relevant meetings, leveraging my professional expertise and independent role, carefully reviewing all proposals presented to the board of directors, and expressing independent opinions, thereby effectively safeguarding the interests of the Company and its shareholders, especially minority shareholders.
I was appointed as an independent director during the election at the Company's second extraordinary general meeting of shareholders held on May 15, 2024. I currently serve as an independent director, a member of the Board's Compensation and Assessment Committee, and a member of the Board's Audit Committee. Below is my performance report for 2025:
I. Basic Information
-
Basic Information of Independent Director Mr. Wang Yi: Formerly served as General Manager of Alibaba Group's Tmall Supermarket Division, General Manager of Tmall Fresh Division, CFO and General Manager of TCL Multimedia's China Division, Executive Director/Senior Vice President of TCL Electronics, Vice President of TCL Industries, and General Manager of the China Marketing Division. Currently serves as General Manager of Shenzhen Mingwei Management Consulting Co., Ltd. and Independent Director of China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
-
Self-Assessment of Independence In accordance with the Management Measures for Independent Directors of Listed Companies and the Self-Regulatory Guidelines No. 1 for Main Board Listed Companies of the Shenzhen Stock Exchange, I conducted a self-assessment of my independence as an independent director of the Company. In 2025, I did not hold any position in the Company other than that of independent director, nor did I hold any position in the Company's major shareholders. There are no interests or other relationships that may hinder my ability to make independent and objective judgments regarding the Company and its major shareholders. My appointment complies with the independence requirements stipulated in the Management Measures for Independent Directors of Listed Companies, and there are no circumstances affecting my independence.
II. Performance in 2025
- Attendance at Board and Shareholder Meetings | Independent Director Name | Total Board Meetings Required | Proxy Attendance | Absences | Attendance at Shareholder Meetings | | --- | --- | --- | --- | --- | | Wang Yi | 15 | 0 | 0 | 8 |
In 2025, the Company held a total of 15 board meetings, and I, as an independent director, was able to attend all meetings on time, carefully reviewing the relevant materials submitted by the Company, listening to management's reports, actively participating in discussions, and providing professional opinions and suggestions. I prudently exercised my voting rights, seriously deliberated on and voted on all board proposals, casting affirmative votes without any dissenting or abstaining votes.
- Participation in Specialized Committees and Independent Director Meetings (1) Compensation and Assessment Committee In 2025, the Company held a total of 8 meetings of the Board's Compensation and Assessment Committee. As the Chair of the Committee, I attended and presided over all meetings, conducting in-depth discussions on proposals such as the revision of the enterprise annuity plan, adjustments to the number and price of restricted stock grants, repurchase and cancellation of restricted stock, conditions for unlocking the second unlocking period of the initial and reserved grant portions, conditions for the third unlocking period not being met, annual assessment results, determining the compensation for the management team, and the annual performance and bonus payment plans, thereby fulfilling my responsibilities and obligations as a member of the Compensation and Assessment Committee.